NASDAQ · APGE
Apogee Therapeutics, Inc.
$135.07$0.00 (0.0%)
Apogee Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.01% below the high.
Loading market information…
NYSE · NVST · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Envista Holdings Corp’s quoted price sits in the upper half of its reported 52-week range, 19.1% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Envista Holdings Corp’s next earnings report is currently expected on Nov 4, 2026, with estimated earnings per share of $0.36. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Envista Holdings Corp’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Envista Holdings Corporation is an enterprise dedicated to the development and distribution of a comprehensive range of dental solutions. These offerings are crucial for the identification, therapeutic intervention, and preventative care of diverse oral health issues, specifically addressing the teeth, gingiva (gums), and their supporting bone structures. The company's principal location is in Brea, California, and it maintains a workforce comprising 12,800 full-time personnel. The firm organizes its business activities into two main divisions: "Specialty Products & Technologies" and "Equipment & Consumables." The Specialty Products & Technologies division concentrates on the creation, fabrication, and promotion of sophisticated dental implant systems, advanced prosthetic devices, and their associated digital treatment software and technological advancements. This segment also provides orthodontic remedies, including bracket systems, clear aligners, and various items for dental laboratories. Conversely, the Equipment & Consumables division is responsible for conceptualizing, producing, and bringing to market a wide array of dental apparatus and vital supplies intended for professional dental clinics. This extensive catalog includes digital imaging instruments, specialized software, and visual or magnification systems; patient treatment units and other essential fixtures for dental practices; complete endodontic kits along with their complementary consumable items; materials and tools for restorative dentistry; rotary cutting tools (burs); impression-making compounds; adhesive agents and dental cements; and products designed for infection control.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:15 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 | May 1, 2025 | $0.24+20.0% vs estimate | $616.90M-2.96% vs estimate |
|---|
| Q4 2024 | Feb 5, 2025 | $0.24+4.35% vs estimate | $652.90M+1.09% vs estimate |
|---|
| Q3 2024 | Oct 30, 2024 | $0.12+33.33% vs estimate | $601.00M-7.21% vs estimate |
|---|
THE ANALYST VIEW
20 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 10 contributors · Median target $28.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$135.07$0.00 (0.0%)
Apogee Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.01% below the high.
$158.92+$1.04 (+0.66%)
GRAIL Inc.’s quoted price sits in the upper half of its reported 52-week range, 4.54% below the high.
$41.25+$0.66 (+1.63%)
Concentra Group Holdings Parent, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.29% below the high.
$168.65+$2.26 (+1.36%)
ICU Medical, Inc.’s quoted price sits in the upper half of its reported 52-week range, 12.55% below the high.
$17.04+$0.06 (+0.35%)
Dyne Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 37.61% below the high.
$22.00+$0.16 (+0.71%)
Privia Health Group, Inc.’s quoted price sits in the lower half of its reported 52-week range, 23.68% below the high.
$41.84+$0.76 (+1.85%)
Supernus Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 29.89% below the high.
$9.61+$0.17 (+1.8%)
DENTSPLY SIRONA Inc.’s quoted price sits in the lower half of its reported 52-week range, 34.89% below the high.
